Zhou Hui, Tang Kun, Xiao Haibing, Zeng Jin, Guan Wei, Guo Xiaolin, Xu Hua, Ye Zhangqun
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Exp Clin Cancer Res. 2015 May 21;34(1):53. doi: 10.1186/s13046-015-0167-0.
There is increasing evidence to suggest that miRNAs play an important role in predicting cancer survival. To identify a panel of miRNA signature that can divided tumor from normal bladder using miRNA expression levels, and to assess the prognostic value of this specific miRNA markers in bladder cancer (BCa).
A comprehensive meta-review of published miRNA expression profiles that compared BCa and adjacent normal tissues was performed to determine candidate miRNAs as prognostic biomarkers for BCa. Vote-counting strategy and Robust Rank Aggregation method were used to identify significant meta-signature miRNAs.
We identified an eight-miRNA signature including three upregulated (miR-141, miR-200c, miR-21) and five downregulated (miR-145, miR-125, miR-199a, let-7c and miR-99a) miRNAs for the prediction of overall survival (OS) using TCGA dataset, and validated in our 48 BCa patients. X-tile plot was used to generate the optimum cut-off point and Kaplan-Meier method was used to calculate OS. A linear prognostic model of eight miRNAs was constructed and weighted by the importance scores from the supervised principal component method to divide patients into high- and low-risk groups. Patients assigned to the high-risk group were associated with poor OS compared with patients in the low-risk group (HR = 5.21, p < 0.001). Our validation cohort of 48 patients confirmed the panel of 8-miRNAs as a reliable prognostic tool for OS in patients with BCa (HR = 5.04, p < 0.001).
The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
越来越多的证据表明,微小RNA(miRNA)在预测癌症生存率方面发挥着重要作用。为了利用miRNA表达水平确定一组能够区分肿瘤与正常膀胱组织的miRNA特征,并评估这些特定miRNA标志物在膀胱癌(BCa)中的预后价值。
对已发表的比较BCa与相邻正常组织的miRNA表达谱进行全面的荟萃综述,以确定候选miRNA作为BCa的预后生物标志物。采用投票计数策略和稳健秩聚合方法来识别显著的荟萃特征miRNA。
我们利用TCGA数据集确定了一个包含8种miRNA的特征,其中3种上调(miR-141、miR-200c、miR-21)和5种下调(miR-145、miR-125、miR-199a、let-7c和miR-99a)的miRNA用于预测总生存期(OS),并在我们的48例BCa患者中进行了验证。使用X-tile图生成最佳截断点,并采用Kaplan-Meier方法计算OS。构建了一个由8种miRNA组成的线性预后模型,并通过监督主成分法的重要性得分进行加权,将患者分为高风险和低风险组。与低风险组患者相比,高风险组患者的OS较差(HR = 5.21,p < 0.001)。我们48例患者的验证队列证实,这8种miRNA组成的特征是BCa患者OS的可靠预后工具(HR = 5.04,p < 0.001)。
本荟萃分析从19个数据集中确定了8种高度显著且一致失调的miRNA。我们还构建了一个由8种miRNA组成的特征,其提供了预测和预后价值,可补充传统的临床病理风险因素。